1 If approved, an effective once-daily oral GLP-1 could significantly expand access by lowering delivery barriers, improving adherence for injection-averse patients, and alleviating distribution constraints often associated with injectable formulations
Though there was a 3-point between-group difference in motor score favoring active treatment, the authors commented that the result was not adjusted for multiple factors, and thus no conclusions could be drawn. What were the most common side effects
Gyncologie Suisse SGGG
LTB4 is a lipid mediator derived from arachidonic acid by the sequential action of 5-lipoxygenase (5-LOX), 5-lipoxygenase-activating protein (FLAP) and LTA4 hydrolase (LTA4H) to stimulate leucocyte functions such as cytokines, chemokinesis, lysosomal enzyme release, superoxide anion production, adhesion to endothelial cells, generation of ROS and so on
2017a) by maintaining the integrity of plasma and organelle (especially mitochondrion) membranes of the cell
